Below, you will find answers to our most commonly asked questions. If you do not find the answer you are looking for, please feel free to contact us at firstname.lastname@example.org.
Age at death <5 years, date of death >1995 and confirmed RSV disease
These actually refer to our funding periods. This project builds on the Lancet publication (GOLD I, Scheltema et al, Lancet 2017). In the GOLD II funding period we have expanded the registry and collected many more cases (and also included nosocomial cases). At this moment we are in the GOLD III funding period.
GOLD I: two articles were published with data from GOLD I (Scheltema et al, Lancet 2017), mainly focusing on the characteristics of the children from the datasets and estimating the potential effect of a maternal vaccination.
GOLD II: with the data from GOLD II, Yvette Löwensteyn has published an article about down syndrome as a risk factor for RSV related mortality (Löwensteyn et al, Pediatr Infect Dis J 2020) and in the next publication with the GOLD II data we will focus on community vs. nosocomial and in-community deaths and in-hospital deaths (specifically in L(M)ICs).
GOLD III: we will focus more on filling in the (knowledge) gaps. We hope to collect more cases from L(M)IC. Moreover, we hope to further develop the model of Nienke Scheltema about the potential effect of a maternal vaccination.
In case you currently do not have the capacity to test for RSV: at this moment, we are unable to work together with hospitals that do not perform RSV testing. However, please do contact us if you are willing to collaborate. If we are setting up a study suitable for a collaboration with you, we could then contact you again.
If you have any questions regarding the online questionnaire, we would be happy to schedule a call to walk through the questionnaire and data submission together.